Examples of using Crossover study in English and their translations into Slovenian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Official/political
-
Programming
The study was a randomized, controlled, single-blinded crossover study.
Znanstveniki izvedli randomizirano, kontrolirano, enojno slepo navzkrižno študijo.A family caregiver's relaxationenhances the gastric motility function of the patient: a crossover study.
Sprostitev družinski negovalec sepovečuje motiliteto želodca funkcijo bolnika: crossover study.The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients≥ 10 years of age are listed in table 3 below.
Farmakokinetični parametri, dobljeni z navzkrižno študijo zdravila ADVATE pri 100 predhodno že zdravljenih bolnikih, starih ≥ 10 let, so navedeni v preglednici 3 spodaj.The effect of idelalisib(150 mg and400 mg) on the QT/QTc interval was evaluated in a placebo- and positive-controlled(moxifloxacin 400 mg) crossover study in 40 healthy subjects.
Učinek idelaliziba(150 mg in 400 mg)na interval QT/QTc so ocenili v navzkrižni študiji, kontrolirani s placebom in pozitivno kontrolo(moksifloksacin 400 mg), s 40 zdravimi osebami.In a double-blind, randomized, placebo-controlled crossover study undertaken at the University of Oklahoma, 25 subjects exercised on a treadmill on two separate occasions.
V dvojno slepi, randomizirani, placebom nadzorovanih cross-over študija na Universityof Oklahoma v ZDA, 25 predmetov izvaja na tekočem traku ob dveh priložnostih.The effect of sunscreen on the absorption of oxybutynin when applied 30 minutes before or 30 minutes after Kenteraapplication was evaluated in a single-dose randomised crossover study(N=16).
Vpliv kreme za sončenje na absorpcijo oksibutinina, pri nanašanju 30 minut pred aplikacijo zdravila Kentera ali 30 minut po njej,so ocenili v randomizirani navzkrižni študiji z enkratnim odmerkom(n= 16).Plasma bimatoprost and timolol concentrations were determined in a crossover study comparing the monotherapy treatments to GANFORT treatment in healthy subjects.
Koncentracije bimatoprosta in timolola v plazmi so določali v navzkrižni študiji za primerjavo učinkovitosti monoterapij z zdravljenjem z zdravilom GANFORT pri zdravih preiskovancih.In a double-blind, crossover study, the reduction in glycosylated haemoglobin levels after 12 weeks dosing was 0.37 percentage points with insulin lispro, compared to 0.03 percentage points for soluble insulin(p= 0.004).
V dvojno slepi navzkrižni študiji so po 12 tednih odmerjanja insulina lispro dosegli 0, 37% zmanjšanje ravni glikiranega hemoglobina v primerjavi z 0, 03% pri topnem insulinu(p= 0, 004).It was titled Randomized, double-blind, placebo-controlled,linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects.
In a crossover study in 27 HIV-infected patients, intracellular carbovir-TP exposures were higher for the abacavir 600 mg once daily regimen(AUC24,ss+ 32%, Cmax24,ss+ 99% and Ctrough+ 18%) compared to the 300 mg twice daily regimen.
V navzkrižni študiji pri 27 bolnikih, okuženih z virusom HIV, je bila znotrajcelična izpostavljenost karbovir-TP-ju večja pri režimu odmerjanja abakavirja 600 mg enkrat na dan AUC24,ss.Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects.
In a crossover study in 27 HIV-infected patients, intracellular carbovir-TP exposures were higher for the abacavir 600 mg once daily regimen(AUC24,ss+ 32%, Cmax24,ss+ 99% and Ctrough+ 18%) compared to the 300 mg twice daily regimen.
V navzkrižni študiji pri 27 bolnikih, okuženih z virusom HIV, je bila znotrajcelična izpostavljenost karbovir-TP-ju večja pri režimu odmerjanja abakavirja 600 mg enkrat na dan(AUC24,ss+ 32%, Cmax24,ss+ 99% in Ctrough+ 18%) kot pri režimu odmerjanja 300 mg dvakrat na dan.Plasma bimatoprost and timolol concentrations were determined in a crossover study comparing the monotherapy treatments to GANFORT(multi-dose formulation) treatment in healthy subjects.
Koncentracije bimatoprosta in timolola v plazmi so določali v navzkrižni študiji za primerjavo učinkovitosti monoterapij z zdravljenjem z zdravilom GANFORT(večodmerna oblika) pri zdravih preiskovancih.In a crossover study in 60 healthy volunteers, intracellular lamivudine-TP pharmacokinetic parameters were similar(AUC24,ss and Cmax24,ss) or lower(Ctrough- 24%) for the lamivudine 300 mg once daily regimen compared to the lamivudine 150 mg twice daily regimen.
V navzkrižni študiji pri 60 zdravih prostovoljcih so bili znotrajcelični farmakokinetični parametri lamivudin-TP-ja pri režimu odmerjanja lamivudina 300 mg enkrat na dan podobni(AUC24,ss in Cmax24,ss) ali manjši(Ctrough- 24%) kot pri režimu odmerjanja lamivudina 150 mg dvakrat na dan.QTcF interval was evaluated in a randomised, placebo and active(moxifloxacin 400 mg once daily)controlled crossover study in 39 healthy adults, with 10 measurements over 12 hours on Day 3.
Interval QTcF so ocenili v randomizirani, s placebom in zdravilno učinkovino(moksifloksacin 400 mg enkrat na dan)kontrolirani navzkrižni študiji pri 39 zdravih odraslih, ki so jim 3. dan v 12 urah naredili 10 meritev.A double-blind, randomised, single dose, crossover study in 24 healthy volunteers showed that the pharmacokinetic profile of Valtropin was comparable to that of the reference product.
V dvojno slepi, randomizirani navzkrižni študiji posameznih odmerkov, ki so jo izvedli na 24 zdravih prostovoljcih, so pokazali, da je farmakokinetični profil zdravila Valtropin primerljiv s farmakokinetičnim profilom referenčnega zdravila.The supportive EUR-1008-M, conducted in the US, was a randomized, double-blind,placebo-controlled, crossover study of 34 patients, ages 7 to 23 years, with EPI due to CF.
Podporna In a randomized, crossover study with 20 healthy adult men, pharmacokinetics was investigated following inhalation of Ventavis(5 mcg iloprost) by the I-Neb AAD in comparison to the ProDose(5 mcg disk).
V randomizirani, navzkrižni študiji, v kateri je sodelovalo 20 zdravih prostovoljcev so primerjali farmakokinetiko zdravila Ventavis(5 mikrogramov iloprost) po aplikaciji skozi nebulatorja I-Neb AAD in ProDose(5 mikrogramov disk).The effect of showering on the absorption of oxybutynin was evaluated in a randomised, steady-state crossover study under conditions of no shower, or showering 1, 2 or 6 hours after Kentera application(N=20).
Vpliv prhanja na absorpcijo oksibutinina so ocenili v randomizirani navzkrižni študiji dinamičnega ravnovesja, pod naslednjimi pogoji: brez prhanja ali s prhanjem 1, 2 ali 6 ur po aplikaciji zdravila Kentera(n= 20).The effect of multiple doses of glycerol phenylbutyrate 13.2 g/day and 19.8 g/day(approximately 69% and 104% of the maximum recommended dailydosage) on QTc interval was evaluated in a randomised, placebo- and active-controlled(moxifloxacin 400 mg), four-treatment-arm, crossover study in 57 healthy subjects.
Učinek večkratnih odmerkov glicerol fenilbutirata 13,2 g/na dan in 19,8 g/na dan(približno 69% in 104% največjega priporočenega dnevnega odmerka) na interval QTc,so ocenjevali v randomizirani navzkrižni študiji s štirimi terapevtskimi kraki, nadzorovani s placebom in zdravilno učinkovino(moksafloksacin 400 mg) pri 57 zdravih preiskovancih.In a multicenter, double-blind, randomized, 2-way, crossover study in 52 outpatients, the skin adhesion of the improved room temperature patch formulation was compared to the cold storage formulation, using the 8 mg/24 h rotigotine patch.
V multicentrični, dvojno slepi, randomizirani, dvosmerni, navzkrižni študiji so pri 52 bolnikih primerjali oprijem na koži formulacije obliža, ki se ga shranjuje na sobni temperaturi, z obližem, ki se ga shranjuje na hladnem.The effect of rilpivirine at the recommended dose of 25 mg once daily on the QTcF interval was evaluated in a randomised, placebo and active(moxifloxacin 400 mg once daily)controlled crossover study in 60 healthy adults, with 13 measurements over 24 hours at steady-state.
Vpliv priporočenega odmerka 25 mg rilpivirina enkrat na dan na interval QTcF so ocenjevali v randomizirani, s placebom in aktivno(z moksifloksacinom 400 mg enkrat na dan)kontrolirani navzkrižni študiji s 60 zdravimi odraslimi, in sicer s 13 meritvami v 24 urah v stanju dinamičnega ravnovesja.This evaluation was conducted in a Phase 1, double-blind, randomized, crossover study to define the ECG effects of amifampridine phosphate at these doses compared to placebo and moxifloxacin(a positive control) in healthy men and women who are slow acetylators(n=52).
Ocenitev je bila izvedena v dvojno slepi, randomizirani, navzkrižni študiji 1. faze za določitev učinkov amifampridinfosfata v teh odmerkih na EKG v primerjavi s placebom in moksifloksacinom(pozitivna kontrola) pri zdravih moških in ženskah, ki so počasni acetilatorji(n= 52).The pharmacokinetic evaluation was repeated for RIXUBIS in an open-label, uncontrolled study with RIXUBIS inmale subjects who participated in the initial PK crossover study and had received prophylaxis with RIXUBIS for 26±1 weeks(mean± SD) and accumulated at least 30 exposure days(EDs) to RIXUBIS.
Farmakokinetično oceno so ponovili za zdravilo RIXUBIS v nezaslepljeni, nekontrolirani A double-blind, randomised, placebo-controlled crossover study has been conducted in which 114 patients who experienced on average 1 to 4 episodes of break through pain(BTP) per day while taking maintenance opioid therapy were entered into an initial open-label titration phase in order to identify an effective dose of PecFent(Study CP043).
Opravili so dvojno slepo, randomizirano, s placebom kontrolirano navzkrižno študijo, v kateri so 114 bolnikov, ki so imeli med vzdrževalnim opioidnim zdravljenjem povprečno po 1 do 4 epizode prebijajoče bolečine(BTP) na dan, vključili v začetno odprto fazo titracije, da bi ugotovili učinkoviti odmerek zdravila PecFent(študija CP043).Pharmacokinetics of iloprost were investigated in a randomised, crossover study with 27 patients, stable on Ventavis 10 microgram/ml inhaled with I-Neb, following inhalation of single doses of 2.5 or 5 microgram iloprost using the Breelib or the I-Neb AAD nebuliser.
Farmakokinetiko iloprosta so preučevali v randomizirani, navzkrižni študiji, v kateri je sodelovalo 27 bolnikov, ki so zdravilo Ventavis 10 mikrogramov/ml inhalirali z nebulatorjem I-Neb in bili stabilni, po inhalaciji enkratnega odmerka 2,5 ali 5 mikrogramov iloprosta z nebulatorjem Breelib ali I-Neb AAD.A double-blind, randomised, single dose, crossover study in 24 healthy volunteers showed that the pharmacokinetic profile of Valtropin was comparable to that of the reference medicinal product. Subcutaneous administration of 0.073 mg/kg body weight of Valtropin resulted in a Cmax of 43.97 ng/ml and an AUC0-24 h of 369.90 ng·h/ml.
V dvojno slepi, randomizirani navzkrižni študiji posameznih odmerkov, ki so jo izvedliprometna 24 zdravih prostovoljcih, so pokazali, da je farmakokinetični profil zdravila Valtropin primerljiv s farmakokinetičnim profilom referenčnega zdravila. Po subkutanem odmerjanju 0,073 mg/kg telesne teže zdravila Valtropin je bila vrednost Cmax 43,97 ng/ml, vrednost AUC0-24 h pa 369,90 ng·h/ml.In single-dose crossover studies of Azomyr 5 mg orodispersible tablets with Azomyr 5 mg conventional tablets, the formulations were bioequivalent.
V navzkrižnih študijah primerjave enkratnega odmerka zdravila Azomyr 5 mg orodisperzibilne tablete z zdravilom Azomyr 5 mg tablete sta se ti dve formulaciji izkazali za bioekvivalentni.
